| Literature DB >> 29066767 |
Yu Pan1, Wenji Wang1, Jinwei Wang2, Li Yang3, Feng Ding4.
Abstract
This study aimed to describe the mortality and risk factors of in-hospital mortality from acute kidney injury (AKI) after non-cardiovascular operation in China based on a nationwide survey about AKI. The study sample was drawn from ISN AKF 0by25 China Consortiums, which is a nationwide, cross-sectional survey from 22 provinces in mainland China. AKI after non-cardiovascular operation was identified according to the 2012 KDIGO AKI creatinine criteria or expanded criteria. In total, 3468 cases were identified as hospital-acquired AKI (HA-AKI). Of these, 1059 cases were defined as AKI after major non-cardiovascular surgery. Post-operative AKI and non-operative AKI were similar in aetiology and in the need for RRT intervention. The all-cause in-hospital mortality was 17.0% (180 of 1059) among patients with AKI after a major surgery. Older age (OR = 1.14, p = 0.046), more severe comorbidities (OR = 9.29, p < 0.001), a history of CVD (OR = 1.85, p = 0.007), more severe peak AKI stage, and being located in the northwest region of China (OR = 2.47, p = 0.012) were all significantly associated with increased in-hospital mortality risk in AKI patients who underwent an operation. AKI after a non-cardiovascular operation has become a huge medical burden in China. The features of operative AKI varied substantially in different regions of China. Increased attention must be paid to the occurrence of potential intrinsic renal AKI when patients are exposed to nephrotoxic factors or comorbidities.Entities:
Mesh:
Year: 2017 PMID: 29066767 PMCID: PMC5654959 DOI: 10.1038/s41598-017-13763-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Study profile.
Characteristics of patients with AKI with or without operations.
| Total | Without operations | With operations |
| |
|---|---|---|---|---|
|
| 2898 | 1839 | 1059 | |
| Age group, years (x ± SD) | 62.3 ± 17.3 | 64.1 ± 17.5 | 59.3 ± 16.5 | <0.001 |
| Aged 18–39 | 308 (10.6%) | 183 (10.0%) | 125 (11.8%) | <0.001 |
| Aged 40–59 | 889 (30.7%) | 510 (27.7%) | 379 (35.8%) | |
| Aged 60–79 | 1159 (40.0%) | 728 (39.6%) | 431 (40.7%) | |
| Aged ≥80 | 542 (18.7%) | 418 (22.7%) | 124 (11.7%) | |
| Male, n (%) | 1884 (65.0%) | 1173 (63.8%) | 711 (67.1%) | 0.068 |
|
| ||||
| North | 791 (27.3%) | 509 (27.7%) | 282 (26.6%) | 0.088 |
| Northwest | 1333 (46.0%) | 824 (44.8%) | 509 (48.1%) | |
| Southeast | 280 (9.7%) | 171 (9.3%) | 109 (10.3%) | |
| Southwest | 494 (17.0%) | 335 (18.2%) | 159 (15.0%) | |
|
| ||||
| Previous CVD | 992 (34.2%) | 756 (41.1%) | 236 (22.3%) | <0.001 |
| Previous HT | 1232 (42.5%) | 846 (46.0%) | 386 (36.5%) | <0.001 |
| Previous DM | 584 (20.2%) | 415 (22.6%) | 169 (16.0%) | <0.001 |
| Pre-exsisting CKD | 684 (23.6%) | 512 (27.8%) | 172 (16.2%) | <0.001 |
| Malignancy | 727 (25.1%) | 400 (21.8%) | 327 (30.9%) | <0.001 |
|
| ||||
| Pre-renal | 1621 (55.9%) | 977 (53.1%) | 644 (60.8%) | <0.001 |
| Intrinsic-renal | 795 (27.4%) | 541 (29.4%) | 254 (24.0%) | 0.002 |
| Post-renal | 133 (4.59%) | 87 (4.73%) | 46 (4.34%) | 0.632 |
| Unclassified | 349 (12.0%) | 234 (12.7%) | 115 (10.9%) | 0.137 |
|
| ||||
| Hypoperfusion | 2319 (80.0%) | 1463 (79.6%) | 856 (80.8%) | 0.408 |
| Nephrotoxicity | 2444 (84.3%) | 1543 (83.9%) | 901 (85.1%) | 0.402 |
| Sepsis | 225 (7.8%) | 138 (7.5%) | 87 (8.2%) | 0.491 |
| Others | 1529 (52.8%) | 877 (47.7%) | 652 (61.6%) | <0.001 |
|
| ||||
| Aminoglycosides | 120 (4.1%) | 55 (3.0%) | 65 (6.1%) | <0.001 |
| Vancomycin | 176 (6.1%) | 94 (5.1%) | 82 (7.7%) | 0.004 |
| Antifungal drugs | 298 (10.3%) | 202 (11.0%) | 96 (9.1%) | 0.101 |
| Antiviral durgs | 177 (6.1%) | 129 (7.0%) | 48 (4.5%) | 0.007 |
| Antibiotics | 1448 (50.0%) | 838 (45.6%) | 610 (57.6%) | <0.001 |
| NSAIDs | 423 (14.6%) | 248 (13.5%) | 175 (16.5%) | 0.0256 |
| Immunosuppressive agents | 154 (5.31%) | 79 (4.3%) | 75 (7.1%) | <0.001 |
| Chemotherapy drugs | 176 (6.1%) | 122 (6.6%) | 54 (5.1%) | 0.096 |
| Chinese herbal medicine | 49 (1.7%) | 36 (2.0%) | 13 (1.2%) | 0.142 |
| others | 1910 (65.9%) | 1266 (68.8%) | 644 (60.8%) | <0.001 |
|
| ||||
| 1 | 1474 (50.9%) | 967 (52.6%) | 507 (47.9%) | 0.032 |
| 2 | 746 (25.7%) | 448 (24.4%) | 298 (28.1%) | |
| 3 | 678 (23.4%) | 424 (23.1%) | 254 (24.0%) | |
|
| ||||
| MODS | 471 (16.3%) | 323 (17.6%) | 148 (14.0%) | 0.012 |
| ARDS | 224 (7.7%) | 141 (7.7%) | 83 (7.8%) | 0.869 |
| SEPSIS | 225 (7.8%) | 138 (7.5%) | 87 (8.2%) | 0.491 |
| SHOCK | 414 (14.3%) | 240 (13.1%) | 174 (16.4%) | 0.012 |
| DIC | 47 (1.62%) | 24 (1.31%) | 23 (2.17%) | 0.075 |
|
| ||||
| Specialist consultant | ||||
| Renal referral | 492 (17.0%) | 348 (18.9%) | 144 (13.6%) | <0.001 |
| RRT | 169 (5.8%) | 111 (6.0%) | 58 (5.5%) | 0.536 |
| RRT indication | 316 (10.9%) | 211 (11.5%) | 105 (9.9%) | 0.195 |
|
| 20 (11–34) | 19 (10–32) | 22 (13–36) | <0.001 |
|
| 572 (20.1%) | 392 (21.7%) | 180 (17.4%) | 0.006 |
|
| ||||
| Recovery | 1717 (59.3%) | 1015 (55.2%) | 702 (66.3%) | <0.001 |
| Recurred* | 138 (4.9%) | 81 (4.5%) | 57 (5.6%) | 0.206 |
| Maintenance RRT* | 60 (47.2%) | 44 (50.0%) | 16 (41.0%) | 0.350 |
|
| 0.018 | |||
| Omission diagnosis, n (%) | 2335 (80.9%) | 1461 (79.7%) | 874 (83.0%) | |
| Delayed diagnosis, n (%) | 139 (4.8%) | 83 (4.5%) | 56 (5.3%) | |
| Immediate diagnosis, n (%) | 412 (14.3%) | 289 (15.8%) | 123 (11.7%) | |
*Data missing for in-hospital mortality in 55 cases (31 in AKI patients without operations vs 24 in AKI patients with operations), for recurred renal prognosis in 99 cases (55 vs 44), for maintenance RRT of renal prognosis in 2771 cases (1751 vs 1020), and for diagnosis in 12 cases (6 vs 6). CVD: Cardiovascular disease; HT: hypertension; DM: diabetes mellitus; CKD: chronic kidney disease; NSAIDs: nonsteroidal anti-inflammatory drugs; MODS: multiple organ dysfunction syndrome; ARDS: Acute respiratory distress syndrome; DIC: disseminated intravascular coagulation; RRT: renal replacement therapy.
Characteristics of patients with postoperative AKI according to regions.
| Total | North | Southeast | Northwest | Southwest |
| |
|---|---|---|---|---|---|---|
|
| 1059 | 282 | 509 | 109 | 159 | |
|
| ||||||
| Age group, years (x ± SD) | 59.3 ± 16.5 | 57.7 ± 17.2 | 59.2 ± 16.0 | 58.6 ± 16.6 | 63.1 ± 16.6 | 0.013 |
| Male, n (%) | 711 (67.1%) | 187 (66.3%) | 336 (66.0%) | 83 (76.2%) | 105 (66.0%) | 0.214 |
|
| ||||||
| Previous CVD | 236 (22.3%) | 80 (28.4%) | 106 (20.8%) | 14 (12.8%) | 36 (22.6%) | 0.006 |
| Previous HT | 386 (36.5%) | 116 (41.1%) | 177 (34.8%) | 36 (33.0%) | 57 (35.9%) | 0.276 |
| Previous DM | 169 (16.0%) | 50 (17.7%) | 67 (13.2%) | 16 (14.7%) | 36 (22.6%) | 0.029 |
| Pre-exsisting CKD | 172 (16.2%) | 54 (19.2%) | 73 (14.3%) | 12 (11.0%) | 33 (20.8%) | 0.053 |
| Malignancy | 327 (30.9%) | 97 (34.4%) | 163 (32.0%) | 28 (25.7%) | 39 (24.5%) | 0.097 |
|
| ||||||
| Abdominal | 366 (34.6%) | 90 (31.9%) | 188 (36.9%) | 31 (28.4%) | 57 (35.9%) | 0.255 |
| Bone/injury | 128 (12.1%) | 16 (5.7%) | 66 (13.0%) | 18 (16.5%) | 28 (17.6%) | <0.001 |
| Thoracic | 82 (7.7%) | 15 (5.3%) | 43 (8.5%) | 11 (10.1%) | 13 (8.2%) | 0.314 |
| neurosurgery | 178 (16.8%) | 48 (17.0%) | 90 (17.7%) | 20 (18.4%) | 20 (12.6%) | 0.474 |
| others | 277 (26.2%) | 92 (32.6%) | 112 (22.0%) | 23 (21.0%) | 50 (31.5%) | 0.002 |
|
| ||||||
| Pre-renal | 644 (60.8%) | 158 (56.0%) | 321 (63.1%) | 84 (77.1%) | 81 (50.9%) | <0.001 |
| Intrinsic-renal | 254 (24.0%) | 99 (35.1%) | 117 (23.0%) | 13 (11.9%) | 25 (15.7%) | <0.001 |
| Post-renal | 46 (4.3%) | 13 (4.6%) | 27 (5.3%) | 0 (0.0%) | 6 (3.8%) | 0.049 |
| Unclassified | 115 (10.9%) | 12 (4.3%) | 44 (8.6%) | 12 (11.0%) | 47 (29.6%) | <0.001 |
|
| 0.040 | |||||
| 1 | 507 (47.9%) | 141 (50.0%) | 238 (46.8%) | 42 (38.5%) | 86 (54.1%) | |
| 2 | 298 (28.1%) | 69 (24.5%) | 146 (28.7%) | 34 (31.2%) | 49 (30.8%) | |
| 3 | 254 (24.0%) | 72 (25.5%) | 125 (24.6%) | 33 (30.3%) | 24 (15.1%) | |
|
| ||||||
| Specialist consultant | ||||||
| Renal referral | 144 (13.6%) | 33 (11.7%) | 68 (13.4%) | 17 (15.6%) | 26 (16.4%) | 0.516 |
| RRT | 58 (5.5%) | 16 (5.7%) | 27 (5.3%) | 6 (5.5%) | 9 (5.7%) | 0.996 |
| RRT indication | 105 (9.9%) | 26 (9.2%) | 49 (9.6%) | 6 (5.5%) | 24 (15.1%) | 0.062 |
|
| 22 (13–36) | 27 (14–48) | 20 (13–33) | 22 (14–34) | 21 (11–36) | 0.002 |
|
| 180 (17.4%) | 48 (17.1%) | 76 (15.5%) | 22 (20.4%) | 34 (21.9%) | 0.244 |
|
| ||||||
| Recovery | 702 (66.3%) | 183 (64.9%) | 333 (65.4%) | 81 (74.3%) | 105 (66.0%) | 0.313 |
| Recurred* | 57 (5.6%) | 25 (9.4%) | 24 (4.9%) | 3 (3.0%) | 5 (3.1%) | 0.014 |
| Maintenance RRT* | 16 (41.0%) | 4 (28.6%) | 7 (43.8%) | 0 (0.0%) | 5 (62.5%) | 0.341 |
|
| 0.429 | |||||
|
| 874 (83.0%) | 239 (85.4%) | 413 (81.5%) | 94 (86.2%) | 128 (81.5%) | |
|
| 56 (5.3%) | 10 (3.6%) | 30 (5.9%) | 5 (4.6%) | 11 (7.0%) | |
|
| 123 (11.7%) | 31 (11.1%) | 64 (12.6%) | 10 (9.2%) | 18 (11.5%) | |
*Data missing for in-hospital mortality in 24 cases (1 in north vs 18 in northwest vs 1 in southeast vs 4 in southwest), for recurred renal prognosis in 44 cases (15 vs 19 vs 10 vs 0), for maintenance RRT of renal prognosis in 1020 cases (268 vs 493 vs 108 vs 151), and for diagnosis in 6 cases (2 vs 2 vs 0 vs 2).
Characteristics of AKI patients with omission diagnosis.
| Total | Without operations | With operations |
| |
|---|---|---|---|---|
|
| 2335 | 1461 | 874 | |
| Aged 18–39 | 241 (10.3%) | 144 (9.9%) | 97 (11.1%) | <0.001 |
| Aged 40–59 | 729 (31.2%) | 412 (28.2%) | 317 (36.3%) | |
| Aged 60–79 | 942 (40.3%) | 573 (39.2%) | 369 (42.2%) | |
| Aged ≥ 80 | 423 (18.1%) | 332 (22.7%) | 91 (10.4%) | |
|
| ||||
| Pre-renal | 1338 (57.3%) | 793 (54.3%) | 545 (62.4%) | <0.001 |
| Intrinsic-renal | 576 (24.7%) | 388 (26.6%) | 188 (21.5%) | 0.006 |
| Post-renal | 110 (4.7%) | 75 (5.1%) | 35 (4.0%) | 0.213 |
| Unclassified | 311 (13.3%) | 205 (14.0%) | 106 (12.1%) | 0.190 |
|
| 0.109 | |||
| 1 | 1331 (57.0%) | 855 (58.5%) | 476 (54.5%) | |
| 2 | 599 (25.7%) | 355 (24.3%) | 244 (27.9%) | |
| 3 | 405 (17.3%) | 251 (17.2%) | 154 (17.6%) | |
Recognition of AKI after major operations by physicians in charge during hospital stay.
| Total | Non-recognised AKI | Delayed recognition of AKI | Timely recognition of AKI |
| |
|---|---|---|---|---|---|
|
| 1053* | 874 | 56 | 123 | 0.003 |
| Aged 18–39 | 97 (11.1%) | 5 (8.9%) | 23 (18.7%) | ||
| Aged 40–59 | 317 (36.3%) | 17 (30.4%) | 42 (34.1%) | ||
| Aged 60–79 | 369 (42.2%) | 20 (35.7%) | 40 (32.5%) | ||
| Aged ≥ 80 | 91 (10.4%) | 14 (25.0%) | 18 (14.6%) | ||
|
| 0.050 | ||||
| Academic hospitals | 741(84.8%) | 42 (75.0%) | 97 (78.9%) | ||
| Local hospitals | 133 (15.2%) | 14 (25.0%) | 26(21.1%) | ||
|
| 0.002 | ||||
| Tertile 1 | 243 (27.8%) | 16 (28.6%) | 24 (19.5%) | ||
| Tertile 2 | 355(40.6%) | 14 (25.0%) | 42 (34.1%) | ||
| Tertile 3 | 276 (31.6%) | 26 (46.4%) | 57 (46.3%) | ||
|
| <0.001 | ||||
| Non-CKD | 758(86.7%) | 42 (75.0%) | 82 (66.7%) | ||
| CKD basis | 116 (13.3%) | 14 (25.0%) | 41 (33.3%) | ||
|
| 0.012 | ||||
| Pre-renal | 545 (62.4%) | 28 (50.0%) | 68 (55.3%) | ||
| Intrinsic-renal | 188 (21.5%) | 20 (35.7%) | 44 (35.8%) | ||
| Post-renal | 35 (4.0%) | 5 (8.9%) | 6 (4.9%) | ||
| Unclassified | 106 (12.1%) | 3 (5.4%) | 5 (4.1%) | ||
|
| <0.001 | ||||
| 1 | 476 (54.5%) | 7 (12.5%) | 23 (18.7%) | ||
| 2 | 244 (27.9%) | 17 (30.4%) | 36 (29.3%) | ||
| 3 | 154 (17.6%) | 32 (57.1%) | 64 (52.0%) |
*Data missing for loss diagnosis (n = 6).
Multivariable logistic regression analysis for factors associated with in-hospital mortality in AKI patients with or without operations.
| variables | Total AKI | AKI Without operations | AKI With operations | |||
|---|---|---|---|---|---|---|
| OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) |
| |
| Age (per 10 years increase) | 1.27 (1.19–1.37) | <0.001 | 1.35 (1.23–1.48) | <0.001 | 1.14 (1.00–1.29) | 0.046 |
| Sex (male vs female) | 1.34 (1.07–1.69) | 0.013 | 1.38 (1.04–1.82) | 0.026 | 1.24 (0.81–1.88), | 0.324 |
| History of CVD (yes or no) | 1.25 (0.98–1.58) | 0.075 | 0.99 (0.74–1.33) | 0.949 | 1.85 (1.18–2.90) | 0.007 |
| Diabetes (yes or no) | 1.10(0.84–1.42) | 0.496 | 1.24 (0.91–1.68) | 0.168 | 0.76 (0.45–1.30) | 0.321 |
| CKD (yes or no) | 1.03 (0.79–1.34) | 0.845 | 0.93 (0.67–1.28) | 0.635 | 1.38 (0.83–2.30) | 0.215 |
|
| ||||||
| Immediate diagnosis | Reference | Reference | Reference | |||
| Omission diagnosis | 0.76 (0.55–1.04) | 0.090 | 1.06 (0.72–1.57) | 0.766 | 0.40 (0.23–0.71) | 0.002 |
| Delayed diagnosis | 1.08 (0.66–1.76) | 0.756 | 1.40 (0.74–2.63) | 0.303 | 0.68 (0.31–1.49) | 0.331 |
| Severe comorbidity (yes or no) | 5.58 (4.64–7.21) | <0.001 | 4.57 (3.49–5.98) | <0.001 | 9.29 (6.19–13.95) | <0.001 |
|
| ||||||
| Stage 1 | Reference | Reference | Reference | |||
| Stage 2 | 2.37 (1.81–3.10) | <0.001 | 2.60 (1.87–3.61) | <0.001 | 2.00 (1.24–3.24) | 0.005 |
| Stage 3 | 3.52 (2.65–4.68) | <0.001 | 4.07 (2.88–5.74) | <0.001 | 2.55 (1.49–4.37) | 0.001 |
|
| ||||||
| North | Reference | Reference | Reference | |||
| Southeast | 0.53 (0.39–0.71) | <0.001 | 0.50 (0.34–0.72) | <0.001 | 0.58 (0.33–1.04) | 0.069 |
| Northwest | 1.84 (1.24–2.74) | 0.002 | 1.62 (0.99–2.65) | 0.053 | 2.47 (1.22–4.99) | 0.012 |
| Southwest | 0.95 (0.58–1.54) | 0.824 | 0.84 (0.47–1.51) | 0.569 | 1.26 (0.50–3.21) | 0.628 |
| RRT indication (yes or no) | 1.84 (1.33–2.54) | <0.001 | 2.22 (1.49–3.33) | <0.001 | 1.20 (0.67–2.15) | 0.541 |
| Renal referral (yes or no) | 0.58 (0.42–0.80) | <0.001 | 0.50 (0.33–0.74) | 0.001 | 0.77 (0.43–1.38) | 0.376 |
| Academic vs local hospital | 1.28 (0.97–1.68) | 0.081 | 1.37 (0.99–1.89) | 0.060 | 1.32 (0.76–2.27) | 0.326 |
|
| ||||||
| Tertile 1 | Reference | Reference | Reference | |||
| Tertile 2 | 0.64 (0.42–0.96) | 0.030 | 0.66 (0.40–1.09) | 0.105 | 0.66 (0.31–1.43) | 0.296 |
| Tertile 3 | 1.40 (0.97–2.04) | 0.075 | 1.29 (0.83–2.02) | 0.258 | 1.69 (0.83–3.45) | 0.149 |